327026-93-7

Basic information

• Product Name: Lensiprazine
• Synonyms: lensiprazine;(2R)-8-[4-[3-(5-Fluoro-1H-indol-3-yl)propyl]-1-piperazinyl]-2-methyl-2H-1,4-benzoxazin-3(4H)-one;(R)-8-(4-(3-(5-fluoro-1H-indol-3-yl)propyl)piperazin-1-yl)-2-methyl-2H-benzo[b][1,4]oxazin-3(4H)-one;(2R)-8-[4-[3-(5-fluoro-1H-indol-3-yl)propyl]piperazin-1-yl]-2-methyl-4H-1,4-benzoxazin-3-one
• CAS NO: 327026-93-7
• Molecular Formula: C24H27FN4O2
• Molecular Weight: 422.5
• Mol File: 327026-93-7.mol

Chemical Properties

• Boiling Point: 668.468 °C at 760 mmHg
• Flash Point: 358.076 °C
• Appearance: /
• Density: 1.262
• PKA: 12.51±0.40(Predicted)
• CAS DataBase Reference: Lensiprazine(CAS DataBase Reference)
• NIST Chemistry Reference: Lensiprazine(327026-93-7)
• EPA Substance Registry System: Lensiprazine(327026-93-7)

Safety Data

• Hazardous Substances Data: 327026-93-7(Hazardous Substances Data)

Usage

Uses

Used in Neurological Conditions:
Lensiprazine is used as a muscle relaxant for the treatment of spasticity and muscle stiffness associated with neurological conditions such as multiple sclerosis, spinal cord injury, and cerebral palsy. It helps to reduce muscle tone and improve movement, thereby enhancing the patients' mobility and overall quality of life.
Used in Adjunct Therapy:
Lensiprazine is used as an adjunct therapy alongside physical therapy and other treatments to manage spasticity more effectively. Its synergistic effect with other therapies can lead to better outcomes in terms of muscle relaxation and improved mobility for patients dealing with spasticity-related conditions.

Upstream product

• 141071-80-9 3-(5-fluoro-1H-indol-3-yl)propan-1-ol 
• 7394-78-7 3-(5-fluoro-1H-indol-3-yl)propanoic acid 
• 6358-08-3 4-chloro-6-nitro-2-aminophenol 
• 327026-91-5 6-chloro-(R)-2-methyl-8-nitro-4H-benzo[1,4]oxazin-3-one 
• 870065-09-1 (R)-2-methyl-8-amino-4H-benzo[1,4]oxazin-3-one 
• 327026-88-0 5-fluoro-3-(3-hydroxypropyl)-1H-indole methanesulfonate 
• 327026-92-6 8-piperazin-1-yl-4H-benzo[1,4]oxazin-(R)-2-methyl-3-one 

Relevant articles and documents

Synthesis, structure-activity relationships, and biological properties of 1-heteroaryl-4-[ω-(1H-indol-3-yl)alkyl]piperazines, novel potential antipsychotics combining potent dopamine D2 receptor antagonism with potent serotonin reuptake inhibition

A series of novel bicyclic 1-heteroaryl-4-[ω-(1H-indol-3-yl)alkyl] piperazines was synthesized and evaluated on binding to dopamine D2 receptors and serotonin reuptake sites. This class of compounds proved to be potent in vitro dopamine D2 receptor antagonists and in addition were highly active as serotonin reuptake inhibitors. Some key representatives showed potent pharmacological in vivo activities after oral dosing in both the antagonism of apomorphine-induced climbing and the potentiation of 5-HTP-induced behavior in mice. On the basis of the preclinical data, 8-{4-[3-(5-fluoro-1H- indol-3-yl)propyl]piperazin-1-yl}-4H-benzo[1,4]oxazin-(R)-2-methyl-3-one (45c, SLV314) was selected for clinical development. In vitro and in vivo studies revealed that 45c has favorable pharmacokinetic properties and a high CNS plasma ratio. Molecular modeling studies showed that the bifunctional activity of 45c can be explained by its ability to adopt two different conformations fitting either the dopamine D2 receptor pharmacophore or the serotonin transporter pharmacophore.

PHENYLPIPERAZINES AS SEROTONIN REUPTAKE INHIBITORS

The invention relates to a novel group of phenylpiperazines having interesting pharmacological properties such as a high affinity for the dopamine D2 receptor and/or the serotonin reuptake site, and the ability to treat conditions related to disturbances